In the presence of acute or chronic myocardial ischemia, myocardial energy metabolism is shifted from the use of aerobic fatty acids (FA) substrate to anaerobic glucose utilization resulting in decreased FA uptake in ischemic regions. This phenomenon may persist as long as 24-30 hours following an acute ischemic event, despite restoration of blood flow and resolution of symptoms and is referred as “ischemic memory”.1 Ischemic memory imaging can be particularly useful in various clinical settings2 as in the case of patients presenting to the emergency department with acute chest pain syndrome.3 We present the first human images of CardioPET (trans-9-F-18-fluoro-3,4-methyleneheptadecanoic acid, FCPHA)4 a F-18 labeled modified FA currently being evaluated in a phase II multicentre clinical trial in patients with a positive SPECT stress test for ischemia.
A 69-year-old man with typical angina was evaluated using bicycle exercise stress-rest Tc-99m-Sestamibi SPECT (Figure 1). As part of a research protocol, prior to coronary angiography, the patient underwent repeat bicycle stress CardioPET imaging at a similar heart rate. CardioPET was injected 8 minutes after peak exercise stress test. CardioPET images (Figure 2) revealed alterations of fatty acid uptake in regions without abnormalities on Tc-99m-Sestamibi-SPECT (Figure 3). It better identified the extent of significant coronary stenosis than did Tc-99m-Sestamibi SPECT as demonstrated by coronary angiography (Figure 4). In addition, regional time-activity curves obtained from the CardioPET data suggested dynamic time-dependent changes in fatty acid retention in ischemic regions different from the non-ischemic regions that need to be further investigated (Figure 5). These preliminary findings suggest a promising role of this new F-18 labeled tracer of FA uptake for the identification of functionally significant coronary artery disease. FA uptake and retention in various pathophysiological conditions may be better understood using the quantitative capabilities of PET technology.
References
Dilsizian V, Bateman T, Bergmann S, Des Prez R, Magram MY, Goodbody AE, et al. Metabolic imaging with β-methyl-p-[123I]-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia. Circulation 2005;112:2169-74.
Dilsizian V. Metabolic adaptation to myocardial ischemia: The role of fatty acid imaging. J Nucl Cardiol 2007;14:S97-9.
Kontos MC, Dilsizian V, Weiland F, DePuey G, Mahmarian JJ, Iskandrian AE, et al. Iodofiltic acid I 123 (BMIPP) fatty acid imaging improves initial diagnosis in emergency department patients with suspected acute coronary syndromes: A multicenter trial. J Am Coll Cardiol 2010;56:290-9.
Shoup T, Elmaleh R, Bonab A, Fischman J. Valuation of trans-9-18F-fluoro-3, 4-methyleneheptadecanoic acid as a PET tracer for myocardial fatty acid imaging. J Nucl Med 2005;46:297-304.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
About this article
Cite this article
Demeure, F., Cerqueira, M.D., Hesse, M. et al. A new F-18 labeled PET tracer for fatty acid imaging. J. Nucl. Cardiol. 22, 391–394 (2015). https://doi.org/10.1007/s12350-014-0012-4
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12350-014-0012-4